Trial to Investigate the Safety and Effectiveness of the KI-362-US1 (YP2.2VM) Intraocular Lens (IOL) in Adult Participants for Correction of Aphakia Following Cataract Extraction
A Prospective, Multicenter, Open-label, Single-arm Clinical Trial to Investigate the Safety and Effectiveness of the KI-362-US1 (YP2.2VM) IOL for Correction of Aphakia Following Cataract Extraction
A study to learn how well an artificial lens, called an intraocular lens (IOL), works in adults who have cataract surgery. During this type of surgery, the eye's natural lens is removed and replaced with an artificial lens to help restore vision.
The main goal of the study is to evaluate vision after the lens is placed in the eye. About one year after surgery, participants' vision will be measured to understand how clearly they can see.
The study will also look at how the lens performs over time, including how well it remains in place in the eye.
The results of this study will help provide more information about how this lens performs in adults undergoing cataract surgery.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Director, Clinical Operations
- Telefonnummer: 919-433-1600
- E-Mail: Clinical@KowaUS.com
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Are able and willing to provide written informed consent, attend all scheduled visits, and comply with all trial procedures and follow-up
- Have a study eye with visually significant cataract for which phacoemulsification cataract extraction and posterior chamber IOL implantation is indicated
- Meet all other inclusion criteria outlined in the clinical study protocol
Exclusion Criteria:
- Have serious systemic disease that could increase operative risk or conditions that can confound the surgical outcome
- Within 30 days of the Screening Visit, use of systemic medications with significant ocular side effects or any medications that could confound the outcome or increase participant risk
- Meet any other exclusion criteria outlined in the clinical study protocol
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: KI-362-US1
Participants in this study receive an artificial lens (intraocular lens) implanted in the eye to replace the eye's natural lens that has been removed due to cataract surgery.
The lens is delivered using a single-use, preloaded device that helps the surgeon place the lens safely and precisely into the natural lens capsule of the eye.
|
Injector and one-piece (1P) monofocal IOL
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of Participants whose BCDVA Achieved 0.30 logMAR or Better at Form 5
Zeitfenster: Baseline (Form 0) through Visit 5 (Form 5), approximately Days 330-390
|
A binary outcome of achieving best-corrected distance visual acuity (BCDVA) of 0.30 logarithm of the minimum angle of resolution (logMAR) or better, or not, at postoperative days 330-390 (Form 5) BCDVA will be measured using Early Treatment Diabetic Retinopathy Study (ETDRS) illuminated charts |
Baseline (Form 0) through Visit 5 (Form 5), approximately Days 330-390
|
|
Proportion of Participants with Incidence of Selected Ocular Adverse Events
Zeitfenster: Baseline through end of study (up to 15 months)
|
This safety outcome measure evaluates whether participants experience any of the following ocular adverse events after treatment, recorded as a binary outcome (occurrence: yes/no). Cumulative adverse events assessed include Cystoid macular edema, Hypopyon, Endophthalmitis, lens dislocation from the posterior chamber, Pupillary block, Retinal detachment, and secondary surgical interventions (excluding posterior capsulotomies). In addition, persistent adverse events are assessed as present or absent, including corneal stroma edema, persistent Cystoid macular edema, Iritis, and elevated intraocular pressure requiring treatment. |
Baseline through end of study (up to 15 months)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of Participants with Lens Axis Misalignment of <10 degrees From Baseline to Form 4
Zeitfenster: Baseline (Form 0) through Visit 4 (Form 4), approximately Days 120-180
|
Evaluation of the rotational stability of the implanted monofocal IOL by assessing changes in lens axis alignment over time.
Stability is determined using binary outcomes (yes/no) based on whether the absolute difference in lens position between baseline (Form 0) and follow-up visit (Form 4) remains within predefined thresholds.
|
Baseline (Form 0) through Visit 4 (Form 4), approximately Days 120-180
|
|
Proportion of Participants with Lens Axis Misalignment of <10 degrees From Baseline to Form 5
Zeitfenster: Baseline (Form 0) through Visit 5 (Form 5), approximately Days 330-390
|
Evaluation of the rotational stability of the implanted monofocal IOL by assessing changes in lens axis alignment over time.
Stability is determined using binary outcomes (yes/no) based on whether the absolute difference in lens position between baseline (Form 0) and follow-up visit (Form 5) remains within predefined thresholds.
|
Baseline (Form 0) through Visit 5 (Form 5), approximately Days 330-390
|
|
Proportion of Participants with Lens Axis Misalignment of <20 degrees From Baseline to Form 4
Zeitfenster: Baseline (Form 0) through Visit 4 (Form 4), approximately Days 120-180
|
Evaluation of the rotational stability of the implanted monofocal IOL by assessing changes in lens axis alignment over time.
Stability is determined using binary outcomes (yes/no) based on whether the absolute difference in lens position between baseline (Form 0) and follow-up visit 4 (Form 4) remains within predefined thresholds.
|
Baseline (Form 0) through Visit 4 (Form 4), approximately Days 120-180
|
|
Proportion of Participants with Lens Axis Misalignment of <20 degrees From Baseline to Form 5
Zeitfenster: Baseline (Form 0) through Visit 5 (Form 5), approximately Days 330-390
|
Evaluation of the rotational stability of the implanted monofocal IOL by assessing changes in lens axis alignment over time.
Stability is determined using binary outcomes (yes/no) based on whether the absolute difference in lens position between baseline (Form 0) and follow-up visit (Form 5) remains within predefined thresholds.
|
Baseline (Form 0) through Visit 5 (Form 5), approximately Days 330-390
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienstuhl: Shona Pendse, MD, MMSc, Kowa Research Institute, Inc.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- KI-362-US1-301
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .